Amgen vs Gilead Sciences
Amgen (AMGN), health care, and Gilead Sciences (GILD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Amgen is worth $248.1B on the stock market and Gilead Sciences $210.7B: Amgen is valued at 18% more. Amgen's operating margin in its latest fiscal year was 24.7% and Gilead Sciences's 34.0%. Over the past year Amgen's share price has moved +34.4% and Gilead Sciences's +31.8%.
Key facts
- Amgen market value
- $248.1B
- Gilead Sciences market value
- $210.7B
- Amgen P/E
- 26.6
- Amgen revenue
- $36.8BFY to 2025-12-31
- Gilead Sciences revenue
- $29.4BFY to 2025-12-31
- Superinvestors holding both
- 5
Market values as of .
| Measure | Amgen | Gilead Sciences |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $248.1Bhigher | $210.7Blower |
| Revenue | $36.8Bhigher | $29.4Blower |
| Earnings | $7.7Blower | $8.5Bhigher |
| Employees | 31,500higher | 17,000lower |
| Total assets | $90.6Bhigher | $59Blower |
| Valuation | ||
| P/E | 26.6 | — |
| P/S | 6.8lower | 7.2higher |
| P/B | 17.3higher | 16.2lower |
| Dividend yield | 2.15%higher | 1.94%lower |
| Profitability | ||
| Operating margin | 24.7%lower | 34.0%higher |
| Balance sheet | ||
| Net assets | $8.7Blower | $22.7Bhigher |
| Total liabilities | $81.9Bhigher | $36.4Blower |
| Total debt | $54.6Bhigher | $24.9Blower |
| Cash on hand | $9.1Bhigher | $7.6Blower |
| Price change | ||
| Today | -0.80%lower | +1.39%higher |
| 1 year | +34.4%higher | +31.8%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (5)
- Josef Lakonishok0.4% / 0.7%
- David Shaw (founder)0.3% / 0.2%
- Fred DiSanto0.2% / 0.3%
- Ken Griffin0.1% / 0.3%
- Dodge & Cox team<0.1% / 1.7%
Amgen only (5)
- Bill Smead5.3%
- Howard Gleicher2.6%
- Primecap team1.5%
- Ken Fisher0.2%
- Mairs & Power team<0.1%
Gilead Sciences only (5)
- Brandon Haley0.9%
- Jim Simons (1938–2024)0.4%
- John Rogers0.3%
- Steve Cohen0.3%
- Ray Dalio (founder)0.2%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Amgen / Gilead Sciences). Who owns AMGN · Who owns GILD
More on Amgen
Further comparisons
Amgen against its closest peers
Gilead Sciences against its closest peers
Learn
Questions and answers
Which is bigger, Amgen or Gilead Sciences?
By market value, Amgen is the larger: $248.1B against $210.7B for Gilead Sciences. By revenue in its latest fiscal year, Amgen is the larger: $36.8B against $29.4B for Gilead Sciences.
Which has the higher operating margin?
Gilead Sciences: 34.0%, against 24.7% for Amgen. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Amgen: 2.15%, against 1.94% for Gilead Sciences. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Amgen: $54.6B, against $24.9B for Gilead Sciences. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Amgen and Gilead Sciences?
In their latest 13F filings, Josef Lakonishok, David Shaw (founder), Fred DiSanto, Ken Griffin and Dodge & Cox team hold both.
Cite this page
Funkfolio, “Amgen vs Gilead Sciences”, data as of 17 November 2026. https://funkfolio.com/compare/amgn-vs-gild
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.